Etoricoxib

As a type of chronic inflammatory disease with a rising global incidence year by year, long-term pain and dysfunction caused by conditions such as osteoarthritis and gouty arthritis seriously affect the quality of life of patients. The advent of selective cyclooxygenase-2 (COX-2) inhibitors provides a safer option for the analgesic and anti-inflammatory treatment of such diseases. Etoricoxib is a second-generation highly selective COX-2 inhibitor. By specifically blocking the synthesis of prostaglandins mediated by COX-2, it not only retains potent anti-inflammatory and analgesic effects, but also greatly reduces the risk of gastrointestinal adverse reactions common to traditional non-steroidal anti-inflammatory drugs. Currently, it is widely used clinically for symptomatic treatment of osteoarthritis in the acute and chronic stages, acute gouty arthritis, and symptomatic management of primary dysmenorrhea, and the applicable population covers patients with chronic pain and inflammation-related diseases of all age groups in adults.

The global etoricoxib market size has maintained steady growth in recent years. In 2023, the overall market size has exceeded 1.8 billion US dollars, of which the Chinese market accounts for approximately 17%, and the compound annual growth rate is maintained at around 8%. In terms of the competitive landscape, the original research product still occupies more than 45% of the market share. 18 domestic enterprises have obtained approval for generic drug preparations, which have been included in the seventh batch of nationally organized centralized drug procurement, with an average price reduction of over 80% for the winning bids. With the implementation and promotion of centralized procurement, the market penetration rate of generic drugs is increasing rapidly, driving the continuous expansion of demand for upstream API.

The original research enterprise of etoricoxib is Merck Sharp & Dohme, with the original research brand name "ARCOXIA", and its Chinese compound patent expired in 2023. Currently, the main dosage form of the original research product on the market is tablet, covering four specifications of 30mg, 60mg, 90mg and 120mg. The original research tablets have been included in the Catalogue of Listed Medicines in China, and are officially recognized as reference preparations. In terms of API registration, as of now, there are more than 30 etoricoxib API registration information on the CDE public platform, of which 22 are in status A, which can be legally supplied for associated preparation declaration and marketing use. A number of domestic enterprises have obtained approval for the marketing of etoricoxib preparations. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of etoricoxib impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of the whole process of drug research and development, quality research and production release.